所长
邵志敏 教授
教授,博士生导师
E-mail: zhimingshao@yahoo.com
 

  邵志敏教授,首批教育部长江学者特聘教授、国家杰青、复旦特聘教授。现任复旦大学肿瘤研究所所长、乳腺癌研究所所长、大外科主任兼乳腺外科主任、中国抗癌协会乳腺癌专业委员会名誉主委、中国抗癌协会靶向治疗专业委员会主任、中国临床肿瘤学会(CSCO)理事、中华医学会肿瘤学分会副主任委员、中国医师协会临床精准医疗专业委员会乳腺癌专业委员会主委、上海市抗癌协会乳腺癌专业委员会名誉主委、上海市医学会肿瘤专科委员会名誉主委、第八届亚洲乳腺癌协会主席、St.Gallen乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,确立三阴性乳腺癌“复旦分型”和精准治疗策略,开展临床试验提高乳腺癌患者预后。已发表有关乳腺癌研究的论著近500篇,其中SCI收录400余篇,被世界医学文献引用逾6000次,主编专著10本。并多次获得国家科技进步二等奖,教育部科技进步一、二等奖,卫生部科技进步一等奖,上海市科技进步一、二、三等奖,领衔团队分别入选教育部创新团队,上海市乳腺肿瘤重点实验室及上海市教委“重中之重临床医学中心B类”项目,上海市重要疾病联合攻关项目。先后主持国家杰青基金、国自然、十五攻关课题、卫生部临床重点项目、211工程II、985、973课题及其他省部级项目30余项。


研究领域:

  主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,确立三阴性乳腺癌“复旦分型”和精准治疗策略,开展临床试验提高乳腺癌患者预后。

研究团队:



代表性论著:

  1. Shao ZM#*, Pang D, Yang HJ, Li W, Wang SS, Cui SD, Liao N, Wang YS, Wang C, Chang YC, Wang H, Kang SY, Seo JH, Shen KW, Laohawiriyakamol S, Jiang ZF, Li JJ, Zhou JL, Althaus B, Mao YX, Eng-Wong J. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol, 2019 Oct 24. [Epub ahead of print] (IF=22.4)
  2. Jiang YZ#, Ma D#, Suo C#, Shi JX#, Xue MZ#, Hu X#, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng YT, Li XN, Zhang CH, Hu PC, Zhang J, Hua Q, Zhang JY, Hou WW, Ren LY, Bao D, Li BY, Yang JC, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu ZM, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P*, Shi LM*, Huang W*, Shao ZM*. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 2019 Mar 18; 35(3):428-440. (IF=23.9)
  3. Jin X#, Xu XE#*, Jiang YZ#, Liu YR, Sun W, Guo YJ, Ren YX, Zuo WJ, Hu X, Huang SL, Shen HJ, Lan F, He YF, Hu GH, Di GH, He XH, Li DQ, Liu SL*, Yu KD*, Shao ZM*. The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Sci Adv, 2019 Mar 6; 5(3): eaat9820. Published online 2019 Mar 6. (IF=11.511)
  4. Xiao Y#, Ma D#, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang WT, Huang W, Hu X, Yu K*, Huang S, Bertucci F, Jiang YZ*, Shao ZM*. Multi-omics profiling reveals distinct microenvironment characterization and suggests immuneescape mechanisms of triple-negative breast cancer. Clin Cancer Res, 2019 Aug 15; 25(16):5002-5014. (IF=10.199)
  5. Zheng YZ#, Xue MZ, Shen HJ, Li XG, Ma D, Gong Y, Liu YR, Qiao F, Xie HY, Lian B, Sun WL, Zhao HY, Yao L, Zuo WJ, Li DQ, Wang P, Hu X*, Shao ZM*. PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. Cancer Res, 2018 Jun 15; 78(12):3190-3206. (IF=9.13)
  6. Chen L#, Yang L#, Yao L#, Kuang XY, Zuo WJ, Li S, Qiao F, Liu YR, Cao ZG, Zhou SL, Zhou XY, Yang WT, Shi JX, Huang W, Hu X*, Shao ZM*. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun, 2018 Apr 10; 9(1):1357.(IF=12.353)
  7. Zuo WJ#, Jiang YZ#*, Wang YJ#, Xu XE#, Hu X, Liu GY, Wu J, Di GH, Yu KD*, Shao ZM*. Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. Clin Cancer Res, 2016 Oct 1; 22(19):4859-4869. (IF=10.199)
  8. Jiang YZ#, Liu YR#, Xu XE#, Jin X#, Hu X, Yu KD*, Shao ZM*. Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res, 2016 Apr 15; 76(8):2105-14.(IF=9.13)
  9. Liu YR#, Jiang YZ#, Xu XE#, Hu X, Yu KD*, Shao ZM*. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clin Cancer Res, 2016 Apr 1; 22(7):1653-62. (IF=10.199)
  10. Yu KD#*, Jiang YZ, Hao S, Shao ZM*. Molecular essence and endocrine responsiceness of estrogen receptor-negative, progesterone receptor-positive and HER2-negative breast cancer. BMC Med, 2015 Oct 5; 13:254. (IF=9.088)
  11. Jiang YZ#, Yu KD#*, Bao J#, Peng WT, Shao ZM*. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. Cancer Res, 2014 Jul 1; 74(13):3399-407. (IF=9.13)
  12. Jiang YZ#, Yu KD#*, Peng WT, Di GH, Wu J, Liu GY, Shao ZM*. Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. Nat Commun, 2014 May 13; 5:3802.(IF=12.353)
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有